Lupin Limited (LUPIN) has received regulatory approval in China for its Oseltamivir Phosphate Oral Suspension, marking the company's first-ever product entry into the Chinese pharmaceutical market— a major milestone in its global expansion strategy.
Oseltamivir Phosphate Oral Suspension (6 mg/mL), developed in partnership with Yabao Pharmaceuticals, will be launched to support influenza treatment and prevention, particularly for pediatric patients, a key focus area for Yabao's established presence in China's children's medicine market.
Oseltamivir is a widely used antiviral medicine for treating and preventing influenza. With this approval, Lupin can now bring a child-friendly liquid formulation to one of the world's largest healthcare markets, improving access to flu care for young patients.
The approved formulation is indicated for:
-Treatment of influenza A and B in patients 2 weeks of age and older
-Prevention of influenza A and B in individuals 1 year of age and older
The oral suspension format is especially important for children and patients who cannot swallow capsules.
Fabrice Egros, President - Corporate Development, Lupin, said the approval represents a strategic step into one of the world's largest pharmaceutical markets, reinforcing the company's commitment to expanding access to high-quality, affordable therapies for pediatric care.
Wei Ren, President, Yabao, called the approval a key milestone in the partnership, highlighting Yabao's dedication to pediatric medicines and its plans to further expand its R&D portfolio for both pediatric and adult chronic disease treatments.
LUPIN has traded between INR 1,836.60 and INR 2,494.00 over the past year. The stock closed today's trading at INR 2,281.80, down 0.12%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.